Organon obtains license for Merck’s novel oral contraceptive

Arnhem, the Netherlands, May 31, 2005 – Akzo Nobel’s human healthcare business, Organon, has been granted worldwide development and marketing rights by Merck KGaA affiliate Laboratoire Théramex for its novel oral contraceptive EMM 310066.

Already successful in Phase II clinical trials, EMM 310066 has been designed to address unmet needs in the oral contraceptive market. By obtaining the license from Théramex, Organon – a world leader in both oral and non-oral contraceptives – is confirming its commitment to bring innovative birth control methods to millions of women all over the world, whether they prefer the pill or an alternative method. “EMM 310066 represents a novel approach for oral contraception with a unique combination of Théramex’ proprietary progestin and the natural estrogen estradiol,” explained Toon Wilderbeek, President of Organon International and Member of Akzo Nobel’s Board of Management. “This late stage opportunity complements our portfolio and reflects our continued commitment to address important unmet medical needs for women seeking a safe and convenient method of contraception, be it oral or otherwise.” Under the terms of the agreement – which is subject to approval by the U.S. Federal Trade Commission under the Hart-Scott Rodino Act – Théramex will receive an upfront payment of EUR 10 million on signing as well as further potential milestone payments and royalties dependant on future product sales. Théramex has also retained rights for marketing and distribution of the product in certain countries. “Merck is pleased to entrust this unique combination discovered and developed by Théramex to Organon,” added Elmar Schnee, Merck’s President of Global Ethical Pharmaceuticals. “We believe Organon is the perfect partner to further develop the potential of EMM 310066, while we at Merck continue to focus our R&D efforts on our main research areas.” Oral contraceptives are used by more than 50 million women worldwide, but the market would clearly benefit from an innovative product such as EMM 310066. - - -